Minodronic acid suppresses gonadotropin-releasing hormone agonist-induced bone remodeling biomarkers: a retrospective pilot study.
BACKGROUND
Estrogen deprivation therapy for myoma/adenomyosis decreases bone mineral density and can only be applied in the short term, as temporizing measures in the premenopausal woman.


OBJECTIVE
To examine the effects of bisphosphonate minodronic acid on markers of bone turnover over a 6-month period in women receiving gonadotropin-releasing hormone agonist (GnRHa).


METHODS
We retrospectively analyzed the medical records of 19 premenopausal patients with myoma/adenomyosis, who received GnRHa (leuprolide acetate, 1.88 mg/month or buserelin acetate, 900 µg/day) for 6 months from January 2014 to December 2014. Eight patients concomitantly received minodronic acid 50 mg every month during GnRHa therapy, and 11 treated with GnRHa alone. To compare these data in a case-controlled study, we analyzed an age-matched group of seven (premature or natural) menopausal women treated with minodronic acid. The primary outcome was percent changes in bone turnover markers in urine at 6 months.


RESULTS
In menopausal women group, minodronic acid (50 mg once-monthly) for 6 months decreased urinary deoxypyridinoline (DPD) and cross-linked N-telopeptides of type 1 collagen (NTX). Women receiving a GnRHa had a significant increase in urinary DPD and TNX at 6 months while minodronic acid during GnRHa therapy improved urinary levels of DPD and NTX to near baseline.


CONCLUSIONS
Minodronic acid treatment appears to be promising in women with secondary bone loss receiving GnRHa treatment.
a Department of Obstetrics and Gynecology , Matsunami General Hospital , Gifu , Japan.
Atsushi
A
Imai
a Department of Obstetrics and Gynecology , Matsunami General Hospital , Gifu , Japan.
Kazutoshi
K
Matsunami
a Department of Obstetrics and Gynecology , Matsunami General Hospital , Gifu , Japan.
Satoshi
S
Ichigo
a Department of Obstetrics and Gynecology , Matsunami General Hospital , Gifu , Japan.
Hiroshi
H
Takagi
D062788:Adenomyosis / Q000188:drug therapy; D000328:Adult; D015415:Biomarkers / Q000652:urine; D016723:Bone Remodeling / Q000187:drug effects; D001862:Bone Resorption / Q000139:chemically induced / Q000517:prevention & control* / Q000652:urine; D002064:Buserelin / Q000009:adverse effects*; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D007889:Leiomyoma / Q000188:drug therapy; D016729:Leuprolide / Q000009:adverse effects*; D008875:Middle Aged; D010865:Pilot Projects; D012189:Retrospective Studies; D014594:Uterine Neoplasms / Q000188:drug therapy
D015415:Biomarkers; D004164:Diphosphonates; D007093:Imidazoles; C087958:YM 529; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide; D002064:Buserelin
Bisphosphonate; GnRHa-induced bone loss; bone turnover markers; minodronic acid